Zydus' Nesher Pharmaceutical gets approval for Nystatin Topical Powder

From USFDA

Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA has received final approval from the USFDA to market Nystatin Topical Powder USP, 100000 units per gram. The drug will be produced at the Nesher Pharmaceutical's manufacturing facility located at St. Louis, USA. Nystatin Topic Powder is an antifungal antibiotic used to treat skin infections caused by yeast.

Powered by Capital Market - Live News